Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Erelzi's Disappearing Indications: Biosimilar Loses Two Of Enbrel's Labeling Claims

09 Feb 2018

• By Sue Sutter

Business men on a Chess board

Related Content

Sandoz’s Erelzi: Biosimilar Pediatric Labeling Strayed From Enbrel

20 Apr 2017

Sandoz Skips Enbrel Biosimilar Patent Dance, Spurs Infringement Suit

01 Mar 2016

FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi

31 Aug 2016

Related Companies

Novartis AG

Amgen, Inc.

Amgen, Inc.

Roche Holding AG

Johnson & Johnson

AbbVie Inc.

Genentech, Inc.

Additional Topics

United States Biosimilars Intellectual Property Legal Issues Regulation Immunology BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.